FDA
-
-
-
-
-
-
-
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Daré Bioscience Participates in Virtual Investor “What This Means” Segment
-
-
-
-
-
-
-
Dare Bioscience regains rights to contraceptive drug from Bayer
-
-
-
-
-
-
-
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Bro
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Dare Bioscience (DARE)
-
-
-
-
-
-
-
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
-
-
-
-
-
-
-
Daré Bioscience (DARE) and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
-
322,748 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

